UndisclosedSPACHealthcare & Life Sciences
TriGemX Bio to go public via TCGX SPAC merger
TriGemX Bio, which is developing elismetrep as a potential first-in-class migraine treatment, signed a definitive business combination agreement with Nasdaq-listed SPAC TCGX Acquisition Corp. The combined public company will be named TriGemX Bio, Inc.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Get healthcare deals like this every morning
The day's biggest deals in five minutes. Free, with no paywalled links.